<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cereb Cortex</journal-id>
<journal-id journal-id-type="iso-abbrev">Cereb. Cortex</journal-id>
<journal-id journal-id-type="publisher-id">cercor</journal-id>
<journal-title-group>
<journal-title>Cerebral Cortex (New York, NY)</journal-title>
</journal-title-group>
<issn pub-type="ppub">1047-3211</issn>
<issn pub-type="epub">1460-2199</issn>
<publisher>
<publisher-name>Oxford University Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28108498</article-id>
<article-id pub-id-type="pmc">5974790</article-id>
<article-id pub-id-type="doi">10.1093/cercor/bhx005</article-id>
<article-id pub-id-type="publisher-id">bhx005</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>mGluR2 versus mGluR3 Metabotropic Glutamate Receptors in Primate Dorsolateral Prefrontal Cortex: Postsynaptic mGluR3 Strengthen Working Memory Networks</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Jin</surname>
<given-names>Lu E</given-names>
</name>
<xref ref-type="aff" rid="bhx005af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Min</given-names>
</name>
<xref ref-type="aff" rid="bhx005af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Galvin</surname>
<given-names>Veronica C</given-names>
</name>
<xref ref-type="aff" rid="bhx005af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lightbourne</surname>
<given-names>Taber C</given-names>
</name>
<xref ref-type="aff" rid="bhx005af1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Conn</surname>
<given-names>Peter Jeffrey</given-names>
</name>
<xref ref-type="aff" rid="bhx005af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arnsten</surname>
<given-names>Amy F T</given-names>
</name>
<xref ref-type="aff" rid="bhx005af1">1</xref>
<xref ref-type="corresp" rid="bhx005cor1"></xref>
<!--<email>constantinos.paspalas@yale.edu</email>-->
</contrib>
<contrib contrib-type="author">
<name>
<surname>Paspalas</surname>
<given-names>Constantinos D</given-names>
</name>
<xref ref-type="aff" rid="bhx005af1">1</xref>
<xref ref-type="corresp" rid="bhx005cor1"></xref>
<!--<email>amy.arnsten@yale.edu</email>-->
</contrib>
</contrib-group>
<aff id="bhx005af1"><label>1</label>Department of Neuroscience, Yale University School of Medicine, New Haven, CT 06510, USA</aff>
<aff id="bhx005af2"><label>2</label>Department of Pharmacology and Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-0697, USA</aff>
<author-notes>
<corresp id="bhx005cor1">Address correspondence to Constantinos D. Paspalas and Amy F.T. Arnsten, Department of Neuroscience, Yale University School of Medicine, 333 Cedar St, New Haven, CT 06510, USA. Email: <email>constantinos.paspalas@yale.edu</email> / <email>amy.arnsten@yale.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>3</month>
<year>2018</year>
</pub-date>
<pub-date iso-8601-date="2017-01-20" pub-type="epub">
<day>20</day>
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>3</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>28</volume>
<issue>3</issue>
<fpage>974</fpage>
<lpage>987</lpage>
<history>
<date date-type="received">
<day>10</day>
<month>8</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>30</day>
<month>11</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com</copyright-statement>
<copyright-year>2017</copyright-year>
<license license-type="oup-standard" xlink:href="https://academic.oup.com/journals/pages/about_us/legal/notices">
<license-p>This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (<ext-link ext-link-type="uri" xlink:href="https://academic.oup.com/journals/pages/about_us/legal/notices">https://academic.oup.com/journals/pages/about_us/legal/notices</ext-link>)</license-p>
</license>
</permissions>
<self-uri xlink:href="bhx005.pdf"></self-uri>
<abstract>
<title>Abstract</title>
<p>The newly evolved circuits in layer III of primate dorsolateral prefrontal cortex (dlPFC) generate the neural representations that subserve working memory. These circuits are weakened by increased cAMP-K<sup>+</sup> channel signaling, and are a focus of pathology in schizophrenia, aging, and Alzheimer's disease. Cognitive deficits in these disorders are increasingly associated with insults to mGluR3 metabotropic glutamate receptors, while reductions in mGluR2 appear protective. This has been perplexing, as mGluR3 has been considered glial receptors, and mGluR2 and mGluR3 have been thought to have similar functions, reducing glutamate transmission. We have discovered that, in addition to their astrocytic expression, mGluR3 is concentrated postsynaptically in spine synapses of layer III dlPFC, positioned to strengthen connectivity by inhibiting postsynaptic cAMP-K<sup>+</sup> channel actions. In contrast, mGluR2 is principally presynaptic as expected, with only a minor postsynaptic component. Functionally, increase in the endogenous mGluR3 agonist, N-acetylaspartylglutamate, markedly enhanced dlPFC Delay cell firing during a working memory task via inhibition of cAMP signaling, while the mGluR2 positive allosteric modulator, BINA, produced an inverted-U dose–response on dlPFC Delay cell firing and working memory performance. These data illuminate why insults to mGluR3 would erode cognitive abilities, and support mGluR3 as a novel therapeutic target for higher cognitive disorders.</p>
</abstract>
<kwd-group>
<kwd>Alzheimer's disease</kwd>
<kwd>dendritic spine</kwd>
<kwd>GRM2</kwd>
<kwd>GRM3</kwd>
<kwd>schizophrenia</kwd>
</kwd-group>
<funding-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">National Institute of Mental Health</named-content>
<named-content content-type="funder-identifier">10.13039/100000025</named-content>
</funding-source>
<award-id>R01AG043430-02</award-id>
</award-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">National Institute on Aging</named-content>
<named-content content-type="funder-identifier">10.13039/100000049</named-content>
</funding-source>
<award-id>R01MH100064-01A1</award-id>
</award-group>
</funding-group>
<counts>
<page-count count="14"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>